Startseite>>Signaling Pathways>> Microbiology & Virology>> Fungal>>Bafilomycin B1

Bafilomycin B1 (Synonyms: Setamycin)

Katalog-Nr.GC18297

Bafilomycin B1 ist ein aus Streptomyces sp. isoliertes Makrolid-Antibiotikum, das grampositive Bakterien und Pilze hemmt und als Inhibitor der K+--abhÄngigen ATPase von E.

Products are for research use only. Not for human use. We do not sell to patients.

Bafilomycin B1 Chemische Struktur

Cas No.: 88899-56-3

Größe Preis Lagerbestand Menge
100μg
55,00 $
Auf Lager
1mg
190,00 $
Auf Lager
5mg
666,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
The bafilomycins are fungal plecomacrolide antibiotics with a 16-membered lactone ring. They inhibit the growth of Gram-positive bacteria and fungi. Bafilomycin B1 is a selective, reversible inhibitor of vacuolar H+-ATPases (V-ATPases), blocking these proton pumps in mammalian, plant, or fungal cells with an IC50 value in the 4-400 nM range. It is at least 1,000-fold less potent at most other types of ATPases. When used at 100 nM, the related macrolide bafilomycin A1 blocks V-ATPase-mediated acidification of lysosomes during autophagy, preventing protein degradation. Remarkably, at only 1 nM, both bafilomycin A1 or B1 dramatically attenuate chloroquine-induced apoptosis of neurons without altering autophagy.

Bewertungen

Review for Bafilomycin B1

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bafilomycin B1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.